TY - STD TI - Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreatedmelanoma. N Engl J Med. 2015:373(1):23–34. ID - ref1 ER - TY - JOUR AU - Leach, D. R. AU - Krummel, M. F. AU - Allison, J. P. PY - 1996 DA - 1996// TI - Enhancement of antitumor immunity by CTLA-4 blockade JO - Science. VL - 271 UR - https://doi.org/10.1126/science.271.5256.1734 DO - 10.1126/science.271.5256.1734 ID - Leach1996 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. M. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. M. AU - Hwu, W. -. J. AU - Topalian, S. L. AU - Hwu, P. PY - 2012 DA - 2012// TI - Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Goswami, S. AU - Apostolou, I. AU - Zhang, J. AU - Skepner, J. AU - Anandhan, S. AU - Zhang, X. PY - 2018 DA - 2018// TI - Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy JO - J Clin Investig VL - 128 UR - https://doi.org/10.1172/JCI99760 DO - 10.1172/JCI99760 ID - Goswami2018 ER - TY - JOUR AU - Hodi, F. S. AU - Lee, S. AU - McDermott, D. F. AU - Rao, U. N. AU - Butterfield, L. H. AU - Tarhini, A. A. PY - 2014 DA - 2014// TI - Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JO - JAMA VL - 312 UR - https://doi.org/10.1001/jama.2014.13943 DO - 10.1001/jama.2014.13943 ID - Hodi2014 ER - TY - JOUR AU - Zhang, J. AU - Dang, F. AU - Ren, J. AU - Wei, W. PY - 2018 DA - 2018// TI - Biochemical aspects of PD-L1 regulation in cancer immunotherapy JO - Trends Biochemical Sci VL - 43 UR - https://doi.org/10.1016/j.tibs.2018.09.004 DO - 10.1016/j.tibs.2018.09.004 ID - Zhang2018 ER - TY - JOUR AU - Hu, Q. AU - Ye, Y. AU - Chan, L. -. C. AU - Li, Y. AU - Liang, K. AU - Lin, A. PY - 2019 DA - 2019// TI - Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression JO - Nature Immunol VL - 20 UR - https://doi.org/10.1038/s41590-019-0400-7 DO - 10.1038/s41590-019-0400-7 ID - Hu2019 ER - TY - JOUR AU - Verma, R. P. AU - Hansch, C. PY - 2007 DA - 2007// TI - Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs JO - Bioorganic Med Chemistry VL - 15 UR - https://doi.org/10.1016/j.bmc.2007.01.011 DO - 10.1016/j.bmc.2007.01.011 ID - Verma2007 ER - TY - JOUR AU - Bonnans, C. AU - Chou, J. AU - Werb, Z. PY - 2014 DA - 2014// TI - Remodelling the extracellular matrix in development and disease JO - Nature Reviews Molecular Cell Biology VL - 15 UR - https://doi.org/10.1038/nrm3904 DO - 10.1038/nrm3904 ID - Bonnans2014 ER - TY - JOUR AU - Kessenbrock, K. AU - Plaks, V. AU - Werb, Z. PY - 2010 DA - 2010// TI - Matrix metalloproteinases: regulators of the tumor microenvironment JO - Cell. VL - 141 UR - https://doi.org/10.1016/j.cell.2010.03.015 DO - 10.1016/j.cell.2010.03.015 ID - Kessenbrock2010 ER - TY - JOUR AU - Li, M. AU - Xing, S. AU - Zhang, H. AU - Shang, S. AU - Li, X. AU - Ren, B. PY - 2016 DA - 2016// TI - A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment JO - Oncol Rep VL - 35 UR - https://doi.org/10.3892/or.2016.4547 DO - 10.3892/or.2016.4547 ID - Li2016 ER - TY - JOUR AU - Mcquibban, G. A. AU - Gong, J. -. H. AU - Wong, J. P. AU - Wallace, J. L. AU - Clark-Lewis, I. AU - Overall, C. M. PY - 2002 DA - 2002// TI - Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo JO - Blood. VL - 100 UR - https://doi.org/10.1182/blood.V100.4.1160.h81602001160_1160_1167 DO - 10.1182/blood.V100.4.1160.h81602001160_1160_1167 ID - Mcquibban2002 ER - TY - JOUR AU - Bergers, G. AU - Brekken, R. AU - McMahon, G. AU - Vu, T. H. AU - Itoh, T. AU - Tamaki, K. PY - 2000 DA - 2000// TI - Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis JO - Nat Cell Biol VL - 2 UR - https://doi.org/10.1038/35036374 DO - 10.1038/35036374 ID - Bergers2000 ER - TY - JOUR AU - Shao, L. AU - Zhang, B. AU - Wang, L. AU - Wu, L. AU - Kan, Q. AU - Fan, K. PY - 2017 DA - 2017// TI - MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells JO - Biochemical And Biophysical Research Communications VL - 493 UR - https://doi.org/10.1016/j.bbrc.2017.10.009 DO - 10.1016/j.bbrc.2017.10.009 ID - Shao2017 ER - TY - JOUR AU - Cathcart, J. AU - Pulkoski-Gross, A. AU - Cao, J. PY - 2015 DA - 2015// TI - Targeting matrix metalloproteinases in cancer: bringing new life to old ideas JO - Genes Diseases VL - 2 UR - https://doi.org/10.1016/j.gendis.2014.12.002 DO - 10.1016/j.gendis.2014.12.002 ID - Cathcart2015 ER - TY - JOUR AU - Rasmussen, H. S. AU - McCann, P. P. PY - 1997 DA - 1997// TI - Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat JO - Pharmacol Ther VL - 75 UR - https://doi.org/10.1016/S0163-7258(97)00023-5 DO - 10.1016/S0163-7258(97)00023-5 ID - Rasmussen1997 ER - TY - STD TI - Steward WP. Marimastat (BB2516): current status of development. Cancer Chemotherapy Pharmacol. 1999;43 Suppl:S56–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10357560. UR - http://www.ncbi.nlm.nih.gov/pubmed/10357560 ID - ref18 ER - TY - JOUR AU - Brown, P. D. PY - 2000 DA - 2000// TI - Ongoing trials with matrix metalloproteinase inhibitors JO - Expert Opinion on Investigational Drugs VL - 9 UR - https://doi.org/10.1517/13543784.9.9.2167 DO - 10.1517/13543784.9.9.2167 ID - Brown2000 ER - TY - STD TI - Summers JB, Davidsen SK, Laboratories A, Ap D, Road AP, Park A. Matrix metalloproteinase inhibitors and cancer. Annual Reports in Medicinal Chemistry Volume 33. 2002;33:131–40. Available from: https://doi.org/10.1016/S0065-7743(08)61078-7. ID - ref20 ER - TY - JOUR AU - Weinstein, J. N. AU - Collisson, E. A. AU - Mills, G. B. AU - Shaw, K. R. AU - Ozenberger, B. A. PY - 2013 DA - 2013// TI - The Cancer Genome Atlas Pan-Cancer analysis project JO - Nat Genet VL - 45 UR - https://doi.org/10.1038/ng.2764 DO - 10.1038/ng.2764 ID - Weinstein2013 ER - TY - JOUR PY - 2013 DA - 2013// TI - The Cancer Genome Atlas Pan-Cancer analysis project JO - Nature Genetics VL - 45 UR - https://doi.org/10.1038/ng.2764 DO - 10.1038/ng.2764 ID - ref22 ER - TY - JOUR AU - Byers, L. A. AU - Diao, L. AU - Wang, J. AU - Saintigny, P. AU - Girard, L. AU - Peyton, M. PY - 2013 DA - 2013// TI - An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1558 DO - 10.1158/1078-0432.CCR-12-1558 ID - Byers2013 ER - TY - JOUR AU - Tang, H. AU - Xiao, G. AU - Behrens, C. AU - Schiller, J. AU - Allen, J. AU - Chow, C. W. PY - 2013 DA - 2013// TI - A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2321 DO - 10.1158/1078-0432.CCR-12-2321 ID - Tang2013 ER - TY - JOUR AU - Wichmann, G. AU - Rosolowski, M. AU - Krohn, K. AU - Kreuz, M. AU - Boehm, A. AU - Reiche, A. PY - 2015 DA - 2015// TI - The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer JO - Int J Cancer VL - 137 UR - https://doi.org/10.1002/ijc.29649 DO - 10.1002/ijc.29649 ID - Wichmann2015 ER - TY - STD TI - Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunity. 2018;812–30. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1074761318301213. UR - http://linkinghub.elsevier.com/retrieve/pii/S1074761318301213 ID - ref26 ER - TY - STD TI - Charoentong P, Angelova M, Charoentong P, Finotello F, Angelova M, Mayer C, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade: cell reports. Cell Rep; 2017;18:248–62. Available from: http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31709-0. UR - http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31709-0 ID - ref27 ER - TY - JOUR AU - Liberzon, A. AU - Birger, C. AU - Thorvaldsdóttir, H. AU - Ghandi, M. AU - Mesirov, J. P. AU - Tamayo, P. PY - 2015 DA - 2015// TI - The molecular signatures database hallmark gene set collection JO - Cell Systems VL - 1 UR - https://doi.org/10.1016/j.cels.2015.12.004 DO - 10.1016/j.cels.2015.12.004 ID - Liberzon2015 ER - TY - STD TI - Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7. ID - ref29 ER - TY - STD TI - Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22(3):609–20. ID - ref30 ER - TY - JOUR AU - Kim, D. AU - Langmead, B. AU - Salzberg, S. L. PY - 2015 DA - 2015// TI - HISAT: a fast spliced aligner with low memory requirements JO - Nat Methods VL - 12 UR - https://doi.org/10.1038/nmeth.3317 DO - 10.1038/nmeth.3317 ID - Kim2015 ER - TY - JOUR AU - Pertea, M. AU - Pertea, G. M. AU - Antonescu, C. M. AU - Chang, T. C. AU - Mendell, J. T. AU - Salzberg, S. L. PY - 2015 DA - 2015// TI - StringTie enables improved reconstruction of a transcriptome from RNA-seq reads JO - Nat Biotechnol VL - 33 UR - https://doi.org/10.1038/nbt.3122 DO - 10.1038/nbt.3122 ID - Pertea2015 ER - TY - STD TI - Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biology. International Society of Matrix Biology; 2015;44–46:200–206. Available from: https://doi.org/10.1016/j.matbio.2015.01.019. ID - ref33 ER - TY - STD TI - Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell research [internet]. Nat Publ Group; 2017;27:109–118. Available from: https://doi.org/10.1038/cr.2016.151. ID - ref34 ER - TY - STD TI - Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines. 2016;4:28. Available from: http://www.mdpi.com/2076-393X/4/3/28. UR - http://www.mdpi.com/2076-393X/4/3/28 ID - ref35 ER - TY - JOUR AU - Brown, S. AU - Bernardo, M. M. AU - Li, Z. H. AU - Kotra, L. P. AU - Tanaka, Y. AU - Fridman, R. PY - 2000 DA - 2000// TI - Potent and selective mechanism-based inhibition of gelafinases JO - J Am Chem Soc VL - 122 UR - https://doi.org/10.1021/ja001461n DO - 10.1021/ja001461n ID - Brown2000 ER - TY - JOUR AU - Krüger, A. AU - Arlt, M. J. E. AU - Gerg, M. AU - Kopitz, C. AU - Bernardo, M. M. AU - Chang, M. PY - 2005 DA - 2005// TI - Antimetastatic activity of a novel mechanism-based gelatinase inhibitor JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-3570 DO - 10.1158/0008-5472.CAN-04-3570 ID - Krüger2005 ER - TY - JOUR AU - Baumeister, S. H. AU - Freeman, G. J. AU - Dranoff, G. AU - Sharpe, A. H. PY - 2016 DA - 2016// TI - Coinhibitory pathways in immunotherapy for cancer JO - Annu Rev Immunol VL - 34 UR - https://doi.org/10.1146/annurev-immunol-032414-112049 DO - 10.1146/annurev-immunol-032414-112049 ID - Baumeister2016 ER - TY - JOUR AU - Wei, S. C. AU - Anang, N. A. A. S. AU - Sharma, R. AU - Andrews, M. C. AU - Reuben, A. AU - Levine, J. H. PY - 2019 DA - 2019// TI - Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies JO - Proc Natl Acad Sci U S A VL - 116 UR - https://doi.org/10.1073/pnas.1821218116 DO - 10.1073/pnas.1821218116 ID - Wei2019 ER - TY - JOUR AU - Steeg, P. S. PY - 2016 DA - 2016// TI - Targeting metastasis JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.25 DO - 10.1038/nrc.2016.25 ID - Steeg2016 ER - TY - JOUR AU - Marie, K. L. AU - Sassano, A. AU - Yang, H. H. AU - Michalowski, A. M. AU - Michael, H. T. AU - Guo, T. PY - 2020 DA - 2020// TI - Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis JO - Nature Communications VL - 11 UR - https://doi.org/10.1038/s41467-019-14085-2 DO - 10.1038/s41467-019-14085-2 ID - Marie2020 ER - TY - JOUR AU - Chen, Q. AU - Bai, H. AU - Wu, W. AU - Huang, G. AU - Li, Y. AU - Wu, M. PY - 2019 DA - 2019// TI - Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention JO - Nano Lett VL - 20 UR - https://doi.org/10.1021/acs.nanolett.9b02182 DO - 10.1021/acs.nanolett.9b02182 ID - Chen2019 ER - TY - JOUR AU - Luo, L. AU - Zubair, M. AU - Liu, C. AU - Xing, J. AU - Udochukwu, O. AU - Fang, Q. PY - 2019 DA - 2019// TI - Biomaterials engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma JO - Biomaterials VL - 223 UR - https://doi.org/10.1016/j.biomaterials.2019.119464 DO - 10.1016/j.biomaterials.2019.119464 ID - Luo2019 ER - TY - JOUR AU - Lei, L. AU - Xu, Z. AU - Hu, X. AU - Lai, Y. AU - Xu, J. AU - Hou, B. PY - 2019 DA - 2019// TI - Bioinspired multivalent peptide nanotubes for sialic acid targeting and imaging-guided treatment of metastatic melanoma JO - Small. VL - 1900157 ID - Lei2019 ER - TY - STD TI - Zhou B, Zhang J, Liu X, Chen H, Ai Y, Cheng K, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell research [internet]. Springer US; 2018;0:1–15. Available from: https://doi.org/10.1038/s41422-018-0090-y. ID - ref45 ER - TY - JOUR AU - Liu, W. AU - Ruan, M. AU - Wang, Y. AU - Song, R. AU - Ji, X. AU - Xu, J. PY - 2018 DA - 2018// TI - Light-triggered biomimetic nanoerythrocyte for tumor-targeted lung metastatic combination therapy of malignant melanoma JO - Small. VL - 1801754 ID - Liu2018 ER - TY - JOUR AU - Juric, V. AU - O’Sullivan, C. AU - Stefanutti, E. AU - Kovalenko, M. AU - Greenstein, A. AU - Barry-Hamilton, V. PY - 2018 DA - 2018// TI - MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0207255 DO - 10.1371/journal.pone.0207255 ID - Juric2018 ER - TY - JOUR AU - Costanza, B. AU - Umelo, I. AU - Bellier, J. AU - Castronovo, V. AU - Turtoi, A. PY - 2017 DA - 2017// TI - Stromal modulators of TGF-β in cancer JO - J Clin Med VL - 6 UR - https://doi.org/10.3390/jcm6010007 DO - 10.3390/jcm6010007 ID - Costanza2017 ER - TY - JOUR AU - Dayer, C. AU - Stamenkovic, I. PY - 2015 DA - 2015// TI - Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-β (TGF-β) activation and fibroblast differentiation JO - J Biol Chem VL - 290 UR - https://doi.org/10.1074/jbc.M114.622274 DO - 10.1074/jbc.M114.622274 ID - Dayer2015 ER - TY - JOUR AU - Yu, Q. AU - Stamenkovic, I. PY - 2000 DA - 2000// TI - Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis JO - Genes Dev VL - 14 ID - Yu2000 ER - TY - JOUR AU - Evanno, E. AU - Godet, J. AU - Piccirilli, N. AU - Guilhot, J. AU - Milin, S. AU - Gombert, J. M. PY - 2017 DA - 2017// TI - Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer JO - Clinical Epigenetics VL - 9 UR - https://doi.org/10.1186/s13148-017-0380-0 DO - 10.1186/s13148-017-0380-0 ID - Evanno2017 ER - TY - STD TI - Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature Communications. 2018:9 Available from: https://doi.org/10.1038/s41467-018-04313-6. ID - ref52 ER - TY - JOUR AU - Liu, H. AU - Kuang, X. AU - Zhang, Y. AU - Ye, Y. AU - Li, J. AU - Liang, L. PY - 2020 DA - 2020// TI - ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis JO - Cancer Cell VL - 37 UR - https://doi.org/10.1016/j.ccell.2020.02.006 DO - 10.1016/j.ccell.2020.02.006 ID - Liu2020 ER - TY - JOUR AU - Lim, S. O. AU - Li, C. W. AU - Xia, W. AU - Cha, J. H. AU - Chan, L. C. AU - Wu, Y. PY - 2016 DA - 2016// TI - Deubiquitination and stabilization of PD-L1 by CSN5 JO - Cancer Cell VL - 30 UR - https://doi.org/10.1016/j.ccell.2016.10.010 DO - 10.1016/j.ccell.2016.10.010 ID - Lim2016 ER - TY - JOUR AU - Zhu, H. AU - Bengsch, F. AU - Svoronos, N. AU - Rutkowski, M. R. AU - Bitler, B. G. AU - Allegrezza, M. J. PY - 2016 DA - 2016// TI - BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression JO - Cell Reports VL - 16 UR - https://doi.org/10.1016/j.celrep.2016.08.032 DO - 10.1016/j.celrep.2016.08.032 ID - Zhu2016 ER - TY - STD TI - Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity Nature [internet]. Nat Publ Group; 2017;549:101–105. Available from: https://doi.org/10.1038/nature23643. ID - ref56 ER - TY - STD TI - Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity. Nature chemical biology [internet]. Springer US; 2019;15:42–50. Available from: https://doi.org/10.1038/s41589-018-0161-x. ID - ref57 ER - TY - JOUR AU - Dorand, R. D. AU - Nthale, J. AU - Myers, J. T. AU - Barkauskas, D. S. AU - Avril, S. AU - Chirieleison, S. M. PY - 2016 DA - 2016// TI - Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity JO - Science. VL - 353 UR - https://doi.org/10.1126/science.aae0477 DO - 10.1126/science.aae0477 ID - Dorand2016 ER - TY - JOUR AU - Winer, A. AU - Adams, S. AU - Mignatti, P. PY - 2018 DA - 2018// TI - Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes JO - Mol Cancer Ther VL - 17 UR - https://doi.org/10.1158/1535-7163.MCT-17-0646 DO - 10.1158/1535-7163.MCT-17-0646 ID - Winer2018 ER - TY - STD TI - Shah MA, Metges J-P, Cunningham D, Shiu K-K, Wyrwicz L, Thai D, et al. A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2019;37. ID - ref60 ER - TY - JOUR AU - Smith, W. M. AU - Purvis, I. J. AU - Bomstad, C. N. AU - Labak, C. M. AU - Velpula, K. K. AU - Tsung, A. J. PY - 2019 DA - 2019// TI - Therapeutic targeting of immune checkpoints with small molecule inhibitors JO - Am J Transl Res VL - 11 ID - Smith2019 ER - TY - JOUR AU - Zhu, H. F. AU - Li, Y. PY - 2018 DA - 2018// TI - Small-molecule targets in tumor immunotherapy JO - Natural Prod Bioprospecting VL - 8 UR - https://doi.org/10.1007/s13659-018-0177-7 DO - 10.1007/s13659-018-0177-7 ID - Zhu2018 ER - TY - JOUR AU - Imai, K. AU - Takaoka, A. PY - 2006 DA - 2006// TI - Comparing antibody and small-molecule therapies for cancer JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1913 DO - 10.1038/nrc1913 ID - Imai2006 ER - TY - JOUR AU - Huck, B. R. AU - Kötzner, L. AU - Urbahns, K. PY - 2018 DA - 2018// TI - Small molecules drive big improvements in immuno-oncology therapies JO - Angewandte Chemie - International Edition VL - 57 UR - https://doi.org/10.1002/anie.201707816 DO - 10.1002/anie.201707816 ID - Huck2018 ER - TY - JOUR AU - Mannello, F. PY - 2011 DA - 2011// TI - What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us ? JO - BMC Medicine VL - 9 UR - https://doi.org/10.1186/1741-7015-9-95 DO - 10.1186/1741-7015-9-95 ID - Mannello2011 ER - TY - JOUR AU - Martins, V. L. AU - Caley, M. AU - Toole, E. A. O. PY - 2013 DA - 2013// TI - Matrix metalloproteinases and epidermal wound repair JO - Cell Tissue Res VL - 351 UR - https://doi.org/10.1007/s00441-012-1410-z DO - 10.1007/s00441-012-1410-z ID - Martins2013 ER - TY - JOUR AU - Cathcart, J. AU - Pulkoski-gross, A. AU - Cao, J. PY - 2015 DA - 2015// TI - ScienceDirect Targeting matrix metalloproteinases in cancer: bringing new life to old ideas JO - Genes Diseases VL - 2 UR - https://doi.org/10.1016/j.gendis.2014.12.002 DO - 10.1016/j.gendis.2014.12.002 ID - Cathcart2015 ER - TY - STD TI - Kuang X, Ye Y. Next generation sequencing facilitates quantitative analysis of IFN-γ induced-MMP2/9 inhibition compared to vehicle control cells’ transcriptomes. Datasets Gene Expression Omnibus. Available from: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi=GSE141585. Accessed 3 Sept 2020. UR - https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi=GSE141585 ID - ref68 ER -